Artificial Intelligence in Aortic Regurgitation

March 17, 2026 updated by: Dr Alex PW Lee, Chinese University of Hong Kong

Artificial Intelligence in Aortic Regurgitation: A Multicenter Randomised Controlled Trial

This research project aims to develop and validate a tool that uses artificial intelligence (AI) to automatically detect and quantify aortic regurgitation (AR). The clinical efficacy of this tool will be established by comparing it to manual diagnostic methods in a multicenter randomized controlled trial. By leveraging deep learning (DL) techniques, the AI system will automate aortic regurgitation (AR) detection, measurement, and diagnosis, addressing challenges like variability in echocardiographic interpretations and the need for specialized expertise. It will integrate multiple echocardiographic parameters to provide accurate, standardized, and efficient AR diagnoses, reducing human error and improving consistency. This tool will enhance diagnostic precision and accessibility, improving clinical outcomes and extending advanced diagnostic capabilities to a broader range of healthcare environments, including resource-limited settings.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
540

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Hong Kong
    • New Territories
      • Hong Kong, New Territories, Hong Kong, Sha Tin
        • Recruiting
        • Division of Cardiology, Department of Medicine and Therapeutics Faculty of Medicine, The Chinese University of Hong Kong
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Confirmed AR diagnosis via TTE and Doppler imaging per guidelines.
  • Age ≥ 18 years.
  • Adequate acoustic window for AR quantification.

Exclusion Criteria:

  • Prior cardiac transplant or implanted cardiac devices.
  • Poor image quality.
  • Pregnancy or lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: AI-Assisted Group
AR severity will be assessed using an AI tool that evaluates grading and key echocardiographic parameters (e.g., EROA, VC, PISA, jet width, and RegVol), along with the time required for assessments.
Diagnostic test: AI-Assisted Group
Participants in this group will undergo aortic regurgitation assessment using an advanced artificial intelligence tool.
Other: Manual Measurement Group
AR severity will be assessed manually by trained sonographers following standard protocols. Cardiologists (ASE level III or equivalent), blinded to patient history and group assignment, will review both AI-generated and manual outputs to make final diagnoses and treatment decisions based solely on the initial assessments.
Other: Manual measurement group
Participants in this group will receive a traditional diagnostic assessment for aortic regurgitation, performed by trained sonographers following standard protocols.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Study Outcomes
Time Frame: This will be recorded from baseline to study completion (20 months)
To compare the accuracy of the AI group and the manual group in distinguishing severe from non-severe AR, using expert cardiologists' (ASE level III or equivalent) assessments as the reference standard.
This will be recorded from baseline to study completion (20 months)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Comparing Accuracy in Differentiating AR Severity Levels
Time Frame: This will be recorded from baseline to study completion (20 months)
To compare the accuracy of the AI group and the manual group in differentiating trace, mild, moderate, and severe aortic regurgitation, using cardiologists' assessments as the reference standard.
This will be recorded from baseline to study completion (20 months)
Assessing deviations in Effective Regurgitant Orifice Area (EROA)
Time Frame: This will be recorded from baseline to study completion (20 months)
The Effective Regurgitant Orifice Area (EROA) assesses the size of a valve opening that leads to backward blood flow in the heart. It is an important metric for evaluating valvular regurgitation and will be measured during echocardiography.
This will be recorded from baseline to study completion (20 months)
Assessing deviations in Vena Contracta (VC)
Time Frame: This will be recorded from baseline to study completion (20 months)
The Vena Contracta (VC) is an important measurement in echocardiography used to evaluate how severe mitral regurgitation is and will be measured during echocardiography.
This will be recorded from baseline to study completion (20 months)
Assessing deviations in Proximal Isovelocity Surface Area (PISA)
Time Frame: This will be recorded from baseline to study completion (20 months)
Proximal Isovelocity Surface Area (PISA) is a method used in echocardiography to evaluate mitral regurgitation and will be measured during echocardiography.
This will be recorded from baseline to study completion (20 months)
Assessing deviations in jet width
Time Frame: This will be recorded from baseline to study completion (20 months)
The jet width is a critical measurement used to assess the severity of aortic regurgitation and will be measured during echocardiography.
This will be recorded from baseline to study completion (20 months)
Assessing deviations in Regurgitant Volume (RegVol)
Time Frame: This will be recorded from baseline to study completion (20 months)
Regurgitant Volume assesses how much blood leaks back into the left atrium during mitral regurgitation and will be measured using Doppler echocardiography.
This will be recorded from baseline to study completion (20 months)
Comparing Assessment Completion Time
Time Frame: The time taken for each method to reach a diagnosis will be recorded from baseline to study completion (20 months)
To compare the time taken by the AI group, the manual group, and the cardiologists to complete their assessments.
The time taken for each method to reach a diagnosis will be recorded from baseline to study completion (20 months)
Tracking 1-Year Outcomes
Time Frame: Participants will be followed up at 6 and 12 months to monitor outcomes, including 1-year all-cause mortality and HFH.
To track 1-year all-cause mortality and heart failure hospitalizations (HFH), comparing outcomes for patients with severe aortic regurgitation identified by the AI and manual groups, separately.
Participants will be followed up at 6 and 12 months to monitor outcomes, including 1-year all-cause mortality and HFH.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Chinese University of Hong Kong

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Semmelweis University
The University of New South Wales
The Prince Charles Hospital
Us2.ai
Toho University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Alex PW Lee, Professor, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 31, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 12, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2024.689-T

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aortic Regurgitation Disease

Clinical Trials on AI-Assisted Group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings